By IDSE News Staff
The FDA does not expect tixagevimab co-packaged with cilgavimab (TIX+CIL) (Evusheld, AstraZeneca) to have the ability to neutralize XBB.1.5, a new emerging omicron subvariant, the agency said.
The CDC estimates XBB.1.5 to be responsible for nearly 30% of variant circulation in the United States.
In October, the FDA released an update adding important information to the authorized Fact Sheets for Evusheld to inform healthcare providers and the public of the increased risk for